Omega-3 triglycerides

Generic Medicine Info
Indications and Dosage
Adult: As a preparation containing 17% eicosapentaenoic acid and 11.5% docosahexaenoic acid: 5 g bid. As a preparation containing 46% eicosapentaenoic acid and 38% docosahexaenoic acid: 2-4 g daily.

Secondary prophylaxis of myocardial infarction
Adult: As a preparation of omega-3 acid ethyl esters containing 46% eicosapentaenoic acid and 38% docosahexaenoic acid: 1 g daily.
Should be taken with food.
Special Precautions
Haemorrhagic disorders or those receiving anticoagulants or other drugs that have antithrombotic activity; asthmatic patients sensitive to aspirin. Monitor hepatic function in patients with hepatic impairment, especially if receiving high doses.
Adverse Reactions
GI disturbances, including nausea, eructation, vomiting, abdominal distension, diarrhoea and constipation. Acne and eczema. Moderate increases in hepatic transaminases in patients with hypertriglyceridaemia.
Description: The omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid are long-chain n-3 polyunsaturated fatty acids, which compete with arachidonic acid for inclusion in cyclo-oxygenase and lipoxygenase pathways. Their actions include hypolipidaemic action (especially a reduction in plasma triglycerides) by reducing very-low-density lipoproteins; anti-inflammatory action, attributed to effects on leukotriene synthesis; and antiplatelet effect, attributed to effects on prostanoid synthesis, which promote vasodilatation, reduction in platelet aggregation, increased bleeding time and decreased platelet counts.
MIMS Class
Dyslipidaemic Agents / Supplements & Adjuvant Therapy
Disclaimer: This information is independently developed by MIMS based on Omega-3 triglycerides from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in